Study wrapper · #405
Effect of Semaglutide on Measured vs Estimated Glomerular Filtration Rate.
Editor's note
This is a post hoc analysis of a randomized, double-blind, placebo-controlled trial in 48 adults with type 2 diabetes and albuminuria, all on empagliflozin, comparing semaglutide 1 mg weekly with placebo over 26 weeks. The precise question is measurement, not outcome: does semaglutide shift the blood markers used to estimate kidney function? Researchers reported that semaglutide was associated with small but statistically significant rises in creatinine and beta-trace protein, no change in cystatin C or beta-2 microglobulin, and — importantly — no significant change in directly measured GFR (via 99mTc-DTPA clearance). The practical takeaway is a nuanced one: a creatinine-based eGFR could suggest apparent kidney-function change that measured GFR does not confirm, and a combined creatinine-plus-cystatin equation tracked true GFR best. Caveats are the tiny sample (n=48), post hoc framing, and a specific population. A careful, clinician-facing measurement finding rather than an efficacy result.
Plain-language abstract
Doctors usually estimate kidney function from blood markers such as creatinine and cystatin C rather than measuring it directly. This study asked whether semaglutide changes those markers in a way that could throw off the estimate. It was a secondary analysis of a randomized, placebo-controlled trial in 48 adults with type 2 diabetes and protein in their urine, all already taking empagliflozin; half received weekly semaglutide and half a dummy injection for 26 weeks. Kidney function was also measured directly using a tracer test. Semaglutide was linked to small increases in creatinine and one marker (beta-trace protein) but no change in two others, and — key point — no real change in directly measured kidney function. So an estimate based on creatinine alone could wrongly suggest kidney function had shifted. A formula combining creatinine and cystatin C matched the true measurement best. The study was small and was a follow-on analysis, so findings need confirmation in larger groups.